Completed NA INTERVENTIONAL 1-arm NCT04318210

Open Label Extension (OLE) of the TDF2 Study, Botswana (TDF2-OLE)

Open Label Extension (OLE) of the Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana

Sponsor: Botswana Ministry of Health

Conditions HIV Infections

Interventions Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg

Updated 7 times since 2020 Last updated: May 11, 2022 Started: Oct 31, 2012 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on HIV Infections, this trial is completed. The trial is conducted by Botswana Ministry of Health and has accumulated 7 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jun 2022 — Dec 2022 [monthly]

Completed NA

▶ Show 2 earlier versions

Jan 2021 — Jun 2022 [monthly]

Completed NA
Apr 2020 — Jan 2021 [monthly]

Completed NA

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Botswana Ministry of Health
Centers for Disease Control and Prevention

Data source: Centers for Disease Control and Prevention

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.